Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02425878 | Ulipristal Acetate 10 mg and Asisted Reproduction | terminated | Phase 3 | 2 | Instituto Valenciano de Infertilidad, IVI VALENCIAOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT00054184 | Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer | terminated | Phase 3 | 350 | CTI BioPharmaINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT00054197 | Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | — | CTI BioPharmaINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT00054210 | Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | — | CTI BioPharmaINDUSTRY | 2 | Oct 5, 2020 | clinicaltrials |
| NCT00551733 | Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | 450 | CTI BioPharmaINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT01773187 | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis | terminated | Phase 3 | 327 | CTI BioPharmaINDUSTRY | 12 | Sep 29, 2020 | clinicaltrials |
| NCT00625898 | BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab(BETH) | terminated | Phase 3 | 3,509 | NSABP Foundation IncNETWORK | 40 | Sep 10, 2020 | clinicaltrials |
| NCT00486512 | Chemoprevention of Colorectal Adenomas | terminated | Phase 3 | 350 | Colotech A/SINDUSTRY | 2 | Sep 3, 2020 | clinicaltrials |
| NCT02929394 | Trabectedin Maintenance Post 1st-line in STS | terminated | Phase 3 | 13 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Sep 2, 2020 | clinicaltrials |
| NCT03745222 | A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer(RATIONALE001) | terminated | Phase 3 | 1 | CelgeneINDUSTRY | 23 | Jul 15, 2020 | clinicaltrials |
| NCT02453490 | Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis | terminated | Phase 3 | 360 | Zhejiang UniversityOTHER | 1 | Jul 14, 2020 | clinicaltrials |
| NCT02718417 | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | terminated | Phase 3 | 998 | PfizerINDUSTRY | 25 | Jul 14, 2020 | clinicaltrials |
| NCT02004184 | Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy(IDA) | terminated | Phase 3 | 230 | Norwegian University of Science and TechnologyOTHER | 1 | Jun 23, 2020 | clinicaltrials |
| NCT03300609 | 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab | terminated | Phase 3 | 4 | University of Southern CaliforniaOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT01774578 | Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer | terminated | Phase 2 / Phase 3 | 135 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT01836432 | Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer(PILLAR) | terminated | Phase 3 | 302 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT03050398 | A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib | terminated | Phase 3 | 8 | Novartis PharmaceuticalsINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT02236936 | Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck(AGMT_HNO_PN) | terminated | Phase 3 | 8 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | May 1, 2020 | clinicaltrials |
| NCT00003645 | Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence | terminated | Phase 3 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT01533207 | Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery | terminated | Phase 3 | 38 | Gynecologic Oncology GroupNETWORK | 8 | Apr 28, 2020 | clinicaltrials |
| NCT00513747 | Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 84 | Alliance for Clinical Trials in OncologyOTHER | 2 | Apr 22, 2020 | clinicaltrials |
| NCT03520959 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702) | terminated | Phase 3 | 1 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 2 | Apr 16, 2020 | clinicaltrials |
| NCT03335059 | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.(RITE-USA) | terminated | Phase 3 | 5 | Medical Enterprises Ltd.INDUSTRY | 1 | Apr 15, 2020 | clinicaltrials |
| NCT01077518 | Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy(A+B) | terminated | Phase 3 | 346 | Novartis PharmaceuticalsINDUSTRY | 17 | Mar 27, 2020 | clinicaltrials |
| NCT00207831 | Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma(UFT RT Phase 3) | terminated | Phase 3 | 219 | Institut Cancerologie de l'OuestOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT02926638 | Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | terminated | Phase 2 / Phase 3 | 9 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 19, 2020 | clinicaltrials |
| NCT02532400 | Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients(COMPETE) | terminated | Phase 3 | 21 | Ruijin HospitalOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT00544700 | Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer | terminated | Phase 3 | 265 | Swiss Cancer InstituteOTHER | 1 | Feb 20, 2020 | clinicaltrials |
| NCT02867280 | Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection | terminated | Phase 3 | 154 | Sun Yat-sen UniversityOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02414165 | The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma(Toca5) | terminated | Phase 2 / Phase 3 | 403 | Tocagen Inc.INDUSTRY | 4 | Feb 7, 2020 | clinicaltrials |
| NCT03670901 | A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) | terminated | Phase 3 | 8 | JHL Biotech, Inc.INDUSTRY | 1 | Jan 9, 2020 | clinicaltrials |
| NCT01902823 | Effect of Cancer Nurse Navigators on Patient Outcomes | terminated | Phase 2 / Phase 3 | 16 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT02174445 | An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years(DECLINE) | terminated | Phase 3 | 14 | Prof. Dr. Nikolas von BubnoffOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT00415246 | Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer | terminated | Phase 3 | 100 | IpsenINDUSTRY | 8 | Nov 22, 2019 | clinicaltrials |
| NCT01313273 | Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients(POSEIDON) | terminated | Phase 3 | 3 | IpsenINDUSTRY | 1 | Nov 22, 2019 | clinicaltrials |
| NCT01021423 | A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).(RENEW) | terminated | Phase 3 | 9 | CelgeneINDUSTRY | 12 | Nov 19, 2019 | clinicaltrials |
| NCT01264887 | Tapentadol in Chronic Malignant Tumour Related Pain | terminated | Phase 3 | 31 | Grünenthal GmbHINDUSTRY | 7 | Nov 4, 2019 | clinicaltrials |
| NCT00505414 | A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine | terminated | Phase 3 | 136 | Grünenthal GmbHINDUSTRY | 6 | Nov 1, 2019 | clinicaltrials |
| NCT02076594 | Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer | terminated | Phase 3 | 171 | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato DigerenteOTHER | 1 | Oct 9, 2019 | clinicaltrials |
| NCT03339622 | Safety and Efficacy of Smoked Cannabis for Improving Quality of Life in Advanced Cancer Patients | terminated | Phase 3 | 8 | Tetra Bio-PharmaINDUSTRY | 1 | Oct 9, 2019 | clinicaltrials |
| NCT00078897 | Selenium for Prevention of Adenomatous Colorectal Polyps | terminated | Phase 3 | 1,621 | University of ArizonaOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT00568633 | Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML | terminated | Phase 3 | 58 | Stanford UniversityOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01599754 | Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients(ATLAS) | terminated | Phase 3 | 724 | SFJ Pharma Ltd. IIINDUSTRY | 9 | Sep 20, 2019 | clinicaltrials |
| NCT02187367 | Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients(EGF) | terminated | Phase 3 | 106 | Bioven EuropeINDUSTRY | 11 | Sep 10, 2019 | clinicaltrials |
| NCT02054338 | A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer(VICTORIA) | terminated | Phase 3 | 1,004 | Pierre Fabre MedicamentINDUSTRY | 0 | Aug 28, 2019 | clinicaltrials |
| NCT02082522 | Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS) | terminated | Phase 3 | 28 | Concordia Laboratories Inc.INDUSTRY | 5 | Aug 28, 2019 | clinicaltrials |
| NCT01014767 | Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors | terminated | Phase 3 | 27 | Tufts Medical CenterOTHER | 4 | Aug 20, 2019 | clinicaltrials |
| NCT01539291 | Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) | terminated | Phase 3 | 161 | Gilead SciencesINDUSTRY | 5 | Aug 20, 2019 | clinicaltrials |
| NCT01659021 | Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 261 | Gilead SciencesINDUSTRY | 11 | Aug 14, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Oct 14, 2020source: clinicaltrials